# Values and preferences of female sex workers in Zimbabwe for long-acting injectable pre-exposure prophylaxis and the dapivirine vaginal ring: results of a mixed-methods research study

**Authors:** Fortunate Machingura, Marc d'Elbée, Tatenda Kujeke, Jasper Maguma, Michelle Rodolph, Rachel Baggaley, Sungai T Chabata, Frances M Cowan

PMC · DOI: 10.1136/bmjgh-2025-021333 · BMJ Global Health · 2026-03-02

## TL;DR

Zimbabwean female sex workers prefer long-acting injectable HIV prevention over other methods, highlighting the need for privacy-focused options tailored to their needs.

## Contribution

The study identifies strong preferences for long-acting injectable PrEP among female sex workers in Zimbabwe, emphasizing privacy and service delivery preferences.

## Key findings

- 74.1% of FSWs expressed interest in long-acting injectable PrEP over alternatives like the dapivirine vaginal ring.
- FSWs showed little trust in public sector providers and preferred PrEP access through sex worker-specific programs.
- Privacy, confidentiality, and respect were identified as key concerns influencing PrEP preferences.

## Abstract

Female sex workers (FSWs) in sub-Saharan Africa are at high risk of HIV acquisition. Here we explore the values and preferences of Zimbabwean FSW for long-acting pre-exposure prophylaxis (PrEP).

We employed mixed methods; focus group discussions (FGD) (n=15), a respondent-driven sampling (RDS) survey (n=4444) from 22 sites across Zimbabwe and a nested discrete choice experiment (DCE) (n=435) conducted in 4/22 sites in 2021. Purposively selected FSWs aged 18 or over who reported being HIV negative were eligible for inclusion in FGDs. Analysis of self-reported HIV negative survey participants was RDS-II weighted. DCE analysis estimated relative preferences. Qualitative and quantitative data were triangulated.

Median age of survey participants was 28 years with IQR of 23–34 years. There was strong concordance across methods by product, provider, service and individual characteristics. Most FSWs indicated that they preferred long-acting injectable (LAI) PrEP to either oral PrEP or dapivirine vaginal ring (DVR). Most were interested in using LAI PrEP (74.1%; n=1835/2392), a few the DVR (10.9%, n=230/2392), and 2.4% (59/2392) and 13.5% (268/2392) either or neither of the two options, respectively. There was little trust in public sector healthcare providers, with most FSWs opting to access PrEP through programmes designed for sex workers (and stating they would miss a prescription refill/repeat injection if the public sector was the only available option). Injectable PrEP addressed privacy and adherence concerns to some extent, although FSWs felt that 6-monthly would be preferable to less frequent injections. Issues of privacy (related to PrEP and being a FSW), confidentiality and respect emerged as key qualitative themes.

FSW had a strong preference for LAI PrEP, but ensuring product choice and user privacy was key. FSW in Eastern and Southern Africa should therefore be prioritised for PrEP choices, with ongoing monitoring and evaluation of services to make sure they are acceptable, effective and evolve as products and delivery options become available.

## Linked entities

- **Chemicals:** dapivirine (PubChem CID 214347)

## Full-text entities

- **Genes:** PRPH2 (peripherin 2) [NCBI Gene 5961] {aka AOFMD, AVMD, CACD2, DS, MDBS1, RDS}, FGD6 (FYVE, RhoGEF and PH domain containing 6) [NCBI Gene 55785] {aka ZFYVE24}
- **Diseases:** cervical cancer (MESH:D002583), addiction (MESH:D019966), drug resistance (MESH:D000069279), lipodystrophy (MESH:D008060), chronic fatigue (MESH:D015673), infection (MESH:D007239), muscle loss (MESH:D009135), HIV (MESH:D015658)
- **Chemicals:** tenofovir disoproxil fumarate (MESH:D000068698), dolutegravir (MESH:C562325), dapivirine (MESH:C481671), LA (MESH:D007811), CAB LA (-), cabotegravir (MESH:C584914), alcohol (MESH:D000438)
- **Species:** Human immunodeficiency virus 1 (no rank) [taxon 11676], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12958915/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12958915/full.md

## References

38 references — full list in the complete paper: https://tomesphere.com/paper/PMC12958915/full.md

---
Source: https://tomesphere.com/paper/PMC12958915